Evidence map›Paper›PMID 41484482›Full record

ArticleCommunications biology2026

A human pathophysiological 3D-bone marrow model reveals immune and stromal cell heterogeneity.

Mariette Giannini, Giulia Campione, Lea Torcq, Sylvain Donadelli, Maroua Bencheikh, Sophia Bounaud, Sandrine Jeanpierre, Kevin Geistlich, Veronique Maguer-Satta, Sylvain Lefort and 1 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mariette Giannini *Centre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Giulia Campione *Centre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Lea TorcqCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.ORCID http://orcid.org/0009-0006-4674-8606
Sylvain DonadelliCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Maroua BencheikhCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Sophia BounaudCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.ORCID http://orcid.org/0009-0002-0739-8085
Sandrine JeanpierreCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Kevin GeistlichCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.
Veronique Maguer-SattaCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France.ORCID http://orcid.org/0000-0002-1556-068X
Sylvain Lefort *Centre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France. sylvain.lefort@lyon.unicancer.fr.ORCID http://orcid.org/0000-0001-7320-4256
Julie Leca *Centre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286 - Centre Léon Bérard -Université Claude Bernard Lyon 1, Lyon, France. julie.leca@lyon.unicancer.fr.ORCID http://orcid.org/0000-0002-6592-0698

Funding

Fondation de France 00143518 / WB-2023-49172Institut National Du Cancer (French National Cancer Institute) INCA_15670 Pediac projectInstitut National Du Cancer (French National Cancer Institute) INCA-PEDIAMOD (Modymime)
6 · The paper itself

Abstract

The bone marrow niche is a complex microenvironment composed of stromal, endothelial, immune and hematopoietic cells. Dysregulated interactions within this niche can contribute to hematological malignancies and also occur in the context of solid cancer metastases. Here, we present a standardized three-dimensional human bone marrow (3D-BOM) model that recapitulates key features of the human niche. Indeed, we show that monocytes/macrophages from different sources acquire enhanced pro-inflammatory phenotype in 3D compared to 2D cultures. Hematopoietic progenitor cells are also influenced by this 3D niche while maintaining stemness characteristics over extended serial culture. Single-cell transcriptomics analysis highlighted human-like stromal and endothelial cells heterogeneity. In addition, we observed monocyte/macrophage and endothelial cell remodeling in the context of acute myeloid leukemia, suggesting dynamic interactions within the 3D-BOM. These findings highlight the potential of this model to investigate cellular dynamics underlying human bone marrow physiology and pathology.

Indexed as

Bone MarrowBone Marrow CellsStromal CellsCell Culture Techniques, Three DimensionalHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMacrophagesMonocytes

Identifiers

PMID41484482
PMCPMC12873127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.